|
業務類別
|
Biotechnology |
|
業務概覽
|
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic propertiesare differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. |
| 公司地址
| 16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446 |
| 電話號碼
| +1 763 392-0767 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.celcuity.com |
| 員工數量
| 87 |
| Dr. Lance G. Laing |
Director, Chief Science Officer, Vice President and Secretary |
美元 351.50K |
01/04/2025 |
| Mr. Brian F. Sullivan |
Chairman of the Board and Chief Executive Officer |
美元 525.00K |
01/04/2025 |
| Ms. Vicky Hahne |
Chief Financial Officer and Principal Accounting Officer |
美元 267.50K |
31/03/2025 |
|
|
| Mr. Charles R. Romp |
Independent Director |
12/02/2026 |
| Dr. Polly A. Murphy, D.V.M.,PhD |
Independent Director |
01/04/2025 |
| Dr. Richard E. Buller, M.D.,PhD |
Independent Director |
01/04/2025 |
| Dr. Leo T. Furcht, M.D. |
Independent Director |
01/04/2025 |
| Dr. Lance G. Laing |
Director, Chief Science Officer, Vice President and Secretary |
01/04/2025 |
| Mr. Richard J. Nigon |
Independent Director |
01/04/2025 |
| Mr. David F. Dalvey |
Independent Director |
01/04/2025 |
| Mr. Brian F. Sullivan |
Chairman of the Board and Chief Executive Officer |
01/04/2025 |
|
|
|
|
